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Dear Editor, 
The effectiveness of the 10-valent pneumococcal conjugate vaccine (PCV10, which contains 
serotype 19F but not serotype 19A) in providing cross-protection against serotype 19A 
disease remains debatable.1-3 In 2011, a 18 month old toddler presented to our hospital with 
fever, cough and shortness of breath for 2 days. Past health was good. She was fully 
vaccinated with four doses of PCV10 (SynflorixTM, GlaxoSmithKlime Inc; primary series 
given at 2, 4 and 6 months of age and booster dose given at age of 12 months). On admission, 
the rectal temperature was 40.6 oC, and oxygenation saturation was 97%. Physical 
examination was significant for diffuse chest wheeze and inflamed tympanic membranes 
bilaterally. Chest radiograph showed some perihilar haziness and no other abnormality was 
detected. The WBC was 21.1 x 109/L (neutrophils 73.8%), hemoglobin was 11.4 g/dL and 
platelet was 456 x 109/L.  
The child was treated empirically with oral amoxycillin-clavulanate (45 mg/kg/day). 
Blood culture taken at admission grew S. pneumoniae after 27 hours of incubation. Following 
the positive blood culture, treatment was switched to intravenous ceftriaxone (50 mg/kg/day). 
Susceptibility testing showed that the isolate was sensitive to all tested antibiotics: penicillin 
(MIC 0.012 µg/ml), cefotaxime (<0.016 µg/ml), chloramphenicol, cotrimoxazole, 
erythromycin, clindamycin and levofloxacin. The child became afebrile one day after 
antibiotic treatment. A total of three days of ceftriaxone and 7 days of oral 
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amoxicillin-clavulanate were given. The S. pneumoniae isolate from the patient was 
identified as serotype 19A.3 Multilocus sequence typing  showed that belonged to ST1201. 3   
In our locality, invasive disease caused by serotype 19A has been found to increase 
shortly after the availability of PCV7 and was associated with expansion of the 
multidrug-resistant ST320 clone.3 Until now, the ST1201-serotype 19A clone has mainly 
been detected in Europe and none has been found in Asia (MLST database at 
http://www.mlst.net, access on 14 September 2013). In Spain, it is one of the circulating 
antibiotic-susceptible clone.4 Immunological studies have showed that after a booster dose in 
the second year of life, the proportions of PCV7- and PCV10-immunized children with OPA 
≥8 against 19A were 30% and 50%, respectively.2 In contrast, 98-100% of children 
immunized with the 13-valent pneumococcal conjugate vaccine had OPA titers ≥8 
post-booster.5 The present report demonstrates bacteremic serotype 19A infection can occur 
in children fully immunized with PCV10. Clinicians should bear this possibility in mind 
when managing febrile children suspected to be suffering from bacteremia.  
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